Below The Knee | Market Signal

When Infrastructure Breaks, Differentiation Wins

Boston Scientific detected a cyberattack on August 25 that disrupted global IT systems and order processing. The company has engaged external cybersecurity experts but hasn't disclosed the attack type, data breach status, or restoration timeline. With over $20 billion in annual revenue and a broad vascular and interventional device portfolio, this isn't a Boston Scientific problem. It's a supply chain problem. Hospitals and distributors relying on Boston Scientific products for vascular intervention, trauma care, and limb salvage procedures just got a reality check on single-source risk.

The same week, the DOJ formally established the National Fraud Enforcement Division with healthcare fraud authority. The division's stated priorities include data-driven investigative techniques and coordinated federal and state partnerships. For wound care and vascular medtech, this signals heightened federal scrutiny of Medicare/Medicaid billing practices, particularly in high-risk categories like skin substitutes, NPWT, and vascular intervention.

And the FDA's Digital Health Center of Excellence released a discussion paper outlining considerations for regulating generative AI-enabled medical devices, requesting public feedback. AI-driven wound assessment tools, vascular imaging systems, and limb salvage decision-support platforms are now in scope for regulatory framework development.

These are systemic infrastructure stresses hitting simultaneously. But here's what actually happened in the category this week.

Winners didn't come from large-cap generalists.

Covalon Technologies reported a 4,285% year-over-year surge in net profit to $2.8 million in Q3 FY26. That's not a typo. The advanced wound care company with specialized antimicrobial coatings and silicone-based dressings is in turnaround mode. PolyNovo reported 16.1% revenue growth to AUD $150 million with positive net profit, U.S. sales exceeding AUD $100 million for the first time. Humacyte published Phase 3 dialysis access trial results in The Lancet, showing ATEV superior performance particularly for women and patients with obesity and diabetes. AOTI achieved unanimous speaker support at a Medicare hearing on topical oxygen therapy coverage for diabetic foot ulcers. AVITA Medical got reimbursement predictability clarity and is guiding toward Q4 2026 cash flow breakeven.

The fund snapshot shows it clearly. CELU up 162.50%, CVALF up 26.94%, BSEM up 8.76%, COLO-R up 4.65%. Meanwhile BSX (Boston Scientific) down 7.35%, GMED down 5.03%, OFIX down 3.80%.

The story isn't that infrastructure stress is killing the category. The story is that when supply chain risk and enforcement risk and regulatory uncertainty all land in the same week, the market reprices large-cap generalists and rewards specialized, differentiated players with clear clinical data and reimbursement clarity.

Covalon's profitability turnaround, PolyNovo's 16% growth, Humacyte's Lancet publication, AOTI's Medicare momentum — these aren't the exception. They're the proof point.

When infrastructure fails, differentiation wins.

Here's the week.

We are 14 days away from IPAWS & Tissue Repair Summit in New Orleans. Below The Knee is the Official Market Intelligence Partner.

September 10–11 | The Ritz-Carlton, New Orleans, LA

ipawssummit.com →

Regulatory | DOJ Establishes National Fraud Enforcement Division with Healthcare Fraud Authority

The DOJ published a Final Rule on August 18, 2026, formally establishing the National Fraud Enforcement Division and delegating authority over healthcare fraud, criminal fraud, tax fraud, and controlled substances matters to the new division, effective August 24. The division's stated priorities include healthcare fraud enforcement using data-driven investigative techniques and coordinated federal and state partnerships. For wound care and vascular medtech markets, this signals heightened federal scrutiny of Medicare/Medicaid billing practices, particularly relevant to high-risk categories such as skin substitutes, NPWT, and vascular intervention where fraud enforcement has historically been concentrated.

The BTK read: This is the structural enforcement pivot. The DOJ is formalizing healthcare fraud as a distinct enforcement priority with dedicated resources and national coordination. For medtech companies operating in CAMP, NPWT, and vascular intervention, this means compliance frameworks just became a competitive moat. Players with defensible billing practices, clear clinical documentation, and transparent reimbursement pathways will outperform those playing at the margins. Expect more audits, more scrutiny, and faster enforcement actions against outliers.

Regulatory | FDA Seeks Public Feedback on Regulating Generative AI Medical Devices

The FDA's Digital Health Center of Excellence has released a discussion paper outlining considerations for regulating generative AI-enabled medical devices and is requesting public feedback. This signals the FDA is actively shaping a regulatory framework for AI-driven diagnostics and decision-support tools, which increasingly intersect with wound assessment, vascular imaging, and limb salvage workflows. For BTK medtech stakeholders, early engagement in this process could influence how AI-powered wound care and vascular diagnostic tools are classified and cleared.

The BTK read: AI regulation is coming. The FDA's discussion paper signals intent to develop a framework, not to delay. For companies building AI-driven wound assessment, tissue perfusion imaging, or vascular decision-support tools, this is the moment to engage in the regulatory dialogue. Early movers who shape the framework will have clearer paths to clearance. Watch for industry comment period closure and FDA response. This will set the template for wound care diagnostics for the next 3-5 years.

Reimbursement | Medicare Hearing Achieves Unanimous Support for AOTI Topical Oxygen Therapy Coverage

AOTI Inc reported unanimous speaker support at a public Medicare hearing on a draft Local Coverage Determination for topical oxygen therapy in diabetic foot ulcers unhealed after four weeks of optimized care. The hearing, hosted by DME MACs under CMS authority, forms part of a 45-day comment period closing September 5, with contractors to finalize the determination thereafter. Broad Medicare coverage would significantly expand patient access for AOTI's TWO2 device beyond current private-pay arrangements, representing a pivotal commercial inflection point for the topical oxygen therapy segment.

The BTK read: Unanimous support at Medicare is rare and meaningful. AOTI's TWO2 device is moving from niche reimbursement to category-level coverage if the determination holds post-comment period. This is the reimbursement clarity win template. Clear clinical positioning (DFU unhealed after 4 weeks optimized care), defined use case, strong evidence. Watch for the finalized LCD by end of Q3. If it lands, topical oxygen therapy becomes a standard-of-care option alongside NPWT and skin substitutes for DFU.

Reimbursement | AVITA Medical Gains Reimbursement Predictability, Eyes Q4 2026 Cash Flow Breakeven

An analyst has issued a Buy rating on AVITA Medical (RCEL), citing improved reimbursement predictability as a key adoption barrier removal for its RECELL, Cohealyx, and PermeaDerm platforms. Management has guided toward cash flow breakeven by Q4 2026, while the RECELL GO international rollout broadens the company's revenue runway. For the skin substitutes market, greater reimbursement clarity could accelerate clinical adoption and strengthen RCEL's competitive positioning against established wound care players.

The BTK read: AVITA's reimbursement clarity moment is the second data point this week showing how clarity drives adoption. The company's guidance toward Q4 2026 cash flow breakeven is meaningful. International rollout with RECELL GO expands addressable market. Watch for Q3 2026 earnings to validate the reimbursement confidence narrative. If adoption accelerates, RCEL becomes the proof point for how reimbursement certainty unlocks scale in skin substitutes.

Market | Covalon Q3 FY26 Net Profit Surges 4,285% YoY to $2.8 Million

Covalon Technologies reported a dramatic 4,285% year-over-year increase in net profit to $2.8 million in Q3 FY26, signaling a major financial turnaround for the advanced wound care and infection prevention company. Covalon specializes in antimicrobial wound care coatings and silicone-based dressings, competing in the advanced wound dressings and skin substitutes segments. This earnings result underscores growing demand for high-performance wound management products and strengthens Covalon's position as a credible player in the BTK wound care market.

The BTK read: A 4,285% net profit swing isn't just earnings volatility. It's a turnaround signal. Covalon's antimicrobial and silicone-based dressing focus positions the company as a differentiated player in advanced wound dressings, not head-to-head with CAMP allografts. The profitability inflection suggests the company has reached scale on its specialized platform and is now converting revenue to profit. Worth tracking for whether this signals broader category health in specialty wound dressings or is specific to Covalon's operational improvements. Watch Q4 guidance.

Market | PolyNovo FY26 Earnings: Revenue Jumps to AUD $150M, Profit Steady

PolyNovo reported full-year 2026 revenue growth of 16.1% to AUD $150 million with positive net profit of AUD $7.3 million. The company demonstrated broad-based growth across its NovoSorb platform in burns, trauma, reconstruction, and complex wound care, with U.S. sales exceeding AUD $100 million for the first time. Manufacturing expansion continues to support growth trajectory.

The BTK read: PolyNovo's 16.1% growth with profitability is the category momentum story. U.S. sales breaking AUD $100M for the first time signals the company is moving from emerging player to established competitor. NovoSorb's broad-based growth across burns, trauma, reconstruction, and complex wound care shows platform durability across use cases. Manufacturing expansion to support growth is the confidence signal. Track PolyNovo as the comparison point against CAMP-pure players. Different market position (synthetic platform vs. allograft), similar reimbursement headwinds, opposite trajectories. Why? Clinical differentiation and procedure volume confidence.

Investment | BioActivX Singapore Raises $3M for Synthetic Skin Substitute Technology

Singapore-based BioActivX has raised $3 million in funding to advance its synthetic skin substitute wound care technology. This investment targets the skin substitute segment, a high-growth area driven by CMS reimbursement scrutiny and demand for cost-effective alternatives to biological grafts. The funding is notable for BTK markets as synthetic skin substitutes face increasing regulatory and reimbursement pressure, making differentiated technology a competitive advantage.

The BTK read: Synthetic skin substitute funding arriving amid CAMP reimbursement compression signals capital is chasing cost-effective alternatives to allografts. BioActivX's $3M raise is modest but meaningful: early-stage capital is moving toward differentiated platforms with cost advantage. This is adjacent to the broader bifurcation story. Allografts are under reimbursement pressure. Synthetics with clear clinical and economic data are attracting capital. Watch for BioActivX's clinical development timeline and regulatory pathway.

Clinical | Humacyte V007 Phase 3 Dialysis Access Results Published in Lancet

Humacyte announced publication of one-year V007 Phase 3 results in The Lancet Digital Health, showing superior performance of its acellular tissue engineered vessel (ATEV) for arteriovenous access in hemodialysis patients. Results demonstrate ATEV outperformed standard AV fistula, particularly for women and patients with obesity and diabetes, complementing earlier V012 interim data supporting a planned supplemental BLA filing in November 2026.

The BTK read: Lancet publication is the clinical validation signal. ATEV's superior performance in high-risk populations (women, obesity, diabetes) is exactly the differentiation story that unlocks market expansion. The complementary data from V007 and V012 trials creates a robust submission package for the supplemental BLA. November filing timeline means regulatory decision likely in Q1-Q2 2027. If approved, dialysis access becomes a second major indication for ATEV, beyond trauma vascular repair. This is commercial inflection point territory.

Regulatory | Humacyte Confirms ATEV Supplemental BLA Filing for Dialysis Access

Humacyte announced it will file a supplemental Biologics License Application in November 2026 to add dialysis access as a second indication for its ATEV product. The V012 Phase 3 study showed patients experienced an average of three additional months without dialysis catheter versus AV fistula standard of care, supporting regulatory momentum for vascular access applications.

The BTK read: The V012 interim data + V007 published full results + November BLA filing = regulatory momentum converging. Three additional catheter-free months is clinically meaningful for dialysis patients and economically significant for payers managing vascular access complications. This is the template for how bioengineered vessels are entering the dialysis access market. Watch for FDA feedback letter or acceptance timeline post-filing.

Market | Kent Imaging Partners with Marathon Medical to Expand VA Wound Imaging Access

Kent Imaging has partnered with Marathon Medical Corporation, an SDVOSB with 20+ years of VA distribution experience, to expand access to its SnapshotNIR and SnapshotGLO wound imaging devices across U.S. Department of Veterans Affairs facilities. The devices provide point-of-care tissue oxygenation and bacterial autofluorescence imaging to support earlier clinical decision-making for chronic wound and PAD patients. This deal opens a significant federal channel for Kent Imaging's diagnostics platform, targeting a high-risk Veteran population with elevated rates of diabetes, peripheral arterial disease, and amputation risk.

The BTK read: Kent Imaging's VA distribution partnership is the channel strategy play. Veterans have elevated PAD and DFU risk, and the VA has incentive to reduce amputation rates. SnapshotNIR and SnapshotGLO providing tissue oxygenation and bacterial imaging at point-of-care is exactly the diagnostic toolkit the VA needs for earlier intervention. This isn't a small channel. Watch for adoption rates and whether the VA expands to other facilities beyond initial pilot sites. This could be a template for how diagnostics companies scale through federal channels.

Market | Globus Medical Acquires Higgs Boson Health for AI-Driven Surgical Intelligence

Globus Medical (NYSE: GMED) announced the acquisition of Higgs Boson Health, a Duke University-incubated digital healthcare company, to build AI-driven surgical intelligence and patient journey tools across its musculoskeletal ecosystem. The deal targets improved outcomes analytics and closed-loop learning for spine, orthopedic trauma, and joint reconstruction procedures. While outside core BTK wound care, the move signals growing medtech investment in AI-powered care episode management relevant to lower limb reconstruction and surgical outcomes tracking.

The BTK read: Globus's Higgs Boson acquisition is the AI outcomes infrastructure play. Building AI-driven surgical intelligence into the musculoskeletal workflow is exactly where medtech is headed. For lower limb reconstruction and limb salvage, closed-loop learning on patient outcomes, complication tracking, and surgical optimization could reshape how centers manage high-risk populations. Watch for integration timeline and whether Globus makes this tool available to non-Globus surgeons. If they open it, this becomes category infrastructure.

Investment | Pentwater Capital Makes $977M New Investment in Kenvue

Pentwater Capital Management LP initiated a new $977.09 million position in Kenvue Inc. (KVUE), the consumer health spinoff from Johnson & Johnson. Kenvue's portfolio includes wound care and skin health consumer products, making this a notable institutional vote of confidence in the consumer health sector. While not a pure-play wound care investment, the significant capital commitment signals institutional interest in consumer-facing health brands with wound and skin care exposure.

The BTK read: Kenvue's $977M institutional capital injection is tangential but telling. A major hedge fund committed nearly $1B to a consumer health platform with wound and skin care exposure. Signals institutional conviction in direct-to-consumer health and wellness trends. For BTK medtech, it's a reminder that wound care markets extend beyond provider-facing clinical solutions into consumer health. Watch Kenvue's earnings for whether their OTC wound care portfolio is seeing adoption momentum.

Regulatory | FDA 510(k) Clearance: Redermax® Antibacterial Wound Matrix (Beijing Kreate Medical)

Beijing Kreate Medical Co., Ltd. received FDA 510(k) clearance for Redermax® Antibacterial Wound Matrix. The product is positioned in the advanced wound dressings segment.

The BTK read: Redermax clearance adds another player to the antimicrobial wound dressing category. Beijing Kreate's entry signals international medtech innovation continuing despite CAMP reimbursement scrutiny. 510(k) pathway indicates predicate comparability. Watch for reimbursement pathway and pricing strategy. Will they compete on cost against established dressings or differentiate on antimicrobial efficacy?

Regulatory | FDA 510(k) Clearance: Vashe Plus Antimicrobial Solution (Urgo Medical North America)

Urgo Medical North America, LLC received FDA 510(k) clearance for Vashe Plus Antimicrobial Solution. This company is tracked in the BTK Innovation Index under Advanced Wound Dressings.

The BTK read: Urgo Medical's Vashe Plus adds to the antimicrobial solution market. Urgo is an established player in advanced wound dressings with global presence. Vashe Plus clearance broadens their antimicrobial portfolio. Watch for clinical positioning relative to enzymatic debriders and topical antimicrobials.

Market | WoundScribe AI Launches Free EMR with Usage-Based AI Charting Pricing

WoundScribe AI introduced a usage-based pricing model for its wound care EMR platform, offering free unlimited seats, patient records, and AI scribe functionality with charges only applied when AI drafts a completed, coded chart. Announced at the Modern Wound Care Management conference, the model is positioned as a clinician-first alternative to traditional subscription EMRs. While not a regulatory or M&A event, the pricing disruption could accelerate EMR adoption among smaller wound care practices and home-based clinicians, indirectly influencing documentation quality and reimbursement compliance across the wound care market.

The BTK read: WoundScribe's usage-based model is the EMR disruption play. Free unlimited seats removes adoption friction for small practices and home care. Usage-based AI charting pricing aligns incentives with clinician productivity. For medtech and reimbursement, better documentation and automated coding reduces billing errors and audit risk. Watch for adoption rates among SNFs, outpatient centers, and home health. If traction holds, this could become infrastructure for the entire sector.

Reimbursement | AMA Sued Over 'Paywalled' Billing Codes

PatientRightsAdvocate.org filed a federal lawsuit challenging the AMA's copyright monopoly on CPT billing codes, arguing that codes incorporated into federal and state law shouldn't be paywalled—patients and providers currently pay $137.89 for a physical copy and $82.50+ annually for access. The suit exposes the structural conflict of interest: the AMA collects an estimated majority of its $296.4 million "books and digital content" revenue from CPT licensing while simultaneously controlling code development and advising CMS on how much those codes should be worth.

The BTK read: The AMA CPT lawsuit is the structural healthcare economics issue. If CPT codes become freely accessible to all providers, it could reduce friction in billing, improve compliance, and lower administrative overhead. For wound care providers already managing complex reimbursement scenarios (CAMP compression, NPWT coverage limits, modular coding), open CPT access could reduce compliance costs. This is a long game. Watch the legal proceedings, but even publicity around the lawsuit could prompt CMS to scrutinize AMA coding recommendations.

Market | Cyberattack Disrupts Boston Scientific Global Operations and Order Processing

Boston Scientific detected a cyberattack on August 25, 2026, causing a network outage that disrupted IT systems globally, including the ability to process and ship customer orders. The company has engaged external cybersecurity experts but has not disclosed the attack type, potential data breach, or restoration timeline. With over $20 billion in annual revenue and a broad vascular and interventional device portfolio, prolonged disruption poses supply chain risk for hospitals and distributors relying on Boston Scientific products.

The BTK read: Boston Scientific's cyberattack is a supply chain stress test. Hospitals depending on Boston Scientific for vascular intervention, thrombectomy, and cardiac devices have zero backup when order processing goes down. This exposes the concentration risk in medtech supply chains. Stryker experienced a similar cyberattack earlier in 2026 and is only now reporting 9% organic growth recovery in Q2 — meaning disruption to operations and order processing cascaded through the quarter. For Boston Scientific, assume a similar recovery timeline: weeks to stabilize order processing, months to fully restore operations, quarterly earnings impact likely. For customers and competitors, it signals the need for vendor diversification or backup strategies. Watch for restoration timeline updates and whether any data breach emerges. Even if fully resolved quickly, this is a reminder of infrastructure fragility in medtech. Companies with geographically diverse manufacturing and distributed order processing are now more valuable.

Woundcare, Limb Salvage, Foot and Ankle and Vascular, all scored, indexed and monitored. Growing evey week - smart watchlists, custom categories, shared team features, control what you see, when you see it and how you are notified - and more coming soon for sales teams.

Market intelligence like you’ve never seen.

intelligence.belowtheknee.co/sign-up →

BTK Wound Care Fund (5D): +0.005% | S&P 500: +0.74% | Dow Jones: +0.55% | NASDAQ: +1.38%

Top 5, five days:

Bottom 5, five days:

The BTK read: The bifurcation thesis holds even with infrastructure stress. CELU's +162.50% is an outlier (likely a technical bounce or restructuring event). CVALF's +26.94%, BSEM's +8.76%, and the small-cap rallies show specialized players gaining on generalists. BSX's -7.35% is cyberattack + supply chain concerns. GMED's -5.03% is the acquisition integration complexity (Higgs Boson deal announced same week as cyberattack). Meanwhile specialists and differentiated players with clear clinical data (Covalon turnaround, PolyNovo growth, Humacyte Lancet, AOTI Medicare momentum) are holding or gaining. Infrastructure risk is selective pressure. Differentiation wins.

Educational model portfolio. Not a real fund. Not investment advice. Performance is model-calculated and unaudited.

We're entering the busiest stretch of the wound care calendar. IPAWS in 14 days. HEAL in September. WUWHS in Malaysia. DFSICON in Bengaluru. ASVS-VSICON in New Delhi. SAWC in Las Vegas. DFCon in Anaheim. More announced weekly.

Scott and the BTK team will be at IPAWS, HEAL, SAWC, and DFCon for sure. Possibly more depending on travel and timing.

If you're heading to any of these conferences, let's meet in person. We're building BTK Intelligence in real time — with input from clinicians, founders, operators, and market veterans. The best insights come from conversations in hallways, not from newsletters.

Email [email protected] if you're at any of these events and want to grab time. Coffee, meals, whiskey bars — whatever works.

See you out there.

August 23–26 | Adelaide, Australia — Wounds Australia 2026 — Adelaide Convention Centre

September 10–11 | New Orleans, LA — IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton (BTK Official Market Intelligence Partner)

September 14–16 | Louisville, KY — NAWCO HEAL Conference 2026

September 23–27 | Kuala Lumpur, Malaysia — WUWHS 2026 – World Union of Wound Healing Societies Congress — Kuala Lumpur Convention Centre

October 1–4 | Bengaluru, India — DFSICON 2026 — Hilton Garden Inn Bengaluru, Embassy Manyata Business Park

October 8–10 | New Delhi, India — ASVS–VSICON 2026 — Pullman & Novotel New Delhi Aerocity

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

Early December (dates TBD) | San Antonio, TX — DFUpdate 2026 (ALPS)

December 9–12 | Phoenix, AZ — Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

See you next week,

-Scott